Following a full submission
AWMSG advice |
|||
| Status: Not recommended | |||
Guanfacine (Intuniv®) is not recommended for use within NHS Wales for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. The case for cost-effectiveness has not been proven. The AWMSG Scrutiny Panel have considered guanfacine suitable for a limited reassessment - see guanfacine (Intuniv®) AWTTC ref 6440 for more details. |
|||
|
|||
Medicine details |
|||
| Medicine name | guanfacine (Intuniv®) | ||
| Formulation | 1 mg, 2 mg, 3 mg and 4 mg prolonged-release tablets | ||
| Reference number | 2361 | ||
| Indication | Treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Intuniv® must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures |
||
| Company | Shire Pharmaceuticals Ltd | ||
| BNF chapter | Central nervous system | ||
| Submission type | Full | ||
| Status | Not recommended | ||
| Advice number | 1216 | ||
| NMG meeting date | 13/04/2016 | ||
| AWMSG meeting date | 18/05/2016 | ||
| Ratification by Welsh Government | 20/06/2016 | ||
| Date of issue | 22/06/2016 | ||
| Further information The AWMSG Scrutiny Panel have considered guanfacine suitable for a limited reassessment - see guanfacine (Intuniv®) AWTTC ref 6440 for more details. |
|||